Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Trump Media and Technology Group Corp (DJT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Trump Media and Technology Group Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Trump Media and Technology Group Corp trades at $8.58 (market cap $2.37B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.8× Trump Media and Technology Group Corp's market cap. Which is the better fit depends on your goals.
| ALNY | DJT | |
|---|---|---|
Market Cap | $39.89B | $2.37B |
Sector | Health | Media |
52-Week High | $491.22 | $19.86 |
52-Week Low | $278.09 | $7.06 |
Enterprise Value | $38.15B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DJT trades at $8.54, down 0.12% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported 2025 revenue of $3.68M but a net loss of -$712.06M, with a negative net income margin of -29,098.97%. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of plans to spin off Truth Social, while the merger with TAE Technologies remains pending.
The outlook is highly speculative with severe financial losses and minimal revenue growth, posing significant risks. Investment potential hinges on the TAE merger and Truth Social's expansion, but high volatility and negative profitability warrant extreme caution for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →
